Fecal Calprotectin and Phenotype Severity in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis |
Talebi, Saeedeh
(Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences)
Day, Andrew S. (Department of Pediatrics, University of Otago (Christchurch)) Rezaiyan, Majid Khadem (Department of Community Medicine, Clinical Research Development Unit of Akbar Hospital, Faculty of Medicine, Mashhad University of Medical Sciences) Ranjbar, Golnaz (Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences) Zarei, Mitra (Department of Knowledge and Information Science, Faculty of Medicine, Mashhad University of Medical Sciences) Safarian, Mahammad (Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences) Kianifar, Hamid Reza (Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences) |
1 | Ellemunter H, Engelhardt A, Schuller K, Steinkamp G. Fecal calprotectin in cystic fibrosis and its relation to disease parameters: a longitudinal analysis for 12 years. J Pediatr Gastroenterol Nutr 2017;65:438-42. DOI |
2 | Belcher CN, Vij N. Protein processing and inflammatory signaling in cystic fibrosis: challenges and therapeutic strategies. Curr Mol Med 2010;10:82-94. DOI |
3 | Stallings VA, Tindall AM, Mascarenhas MR, Maqbool A, Schall JI. Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: a randomized controlled trial. PLoS One 2020;15:e0232685. DOI |
4 | Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Int J Surg 2010;8:336-41. DOI |
5 | Anderson JL, Miles C, Tierney AC. Effect of probiotics on respiratory, gastrointestinal and nutritional outcomes in patients with cystic fibrosis: a systematic review. J Cyst Fibros 2017;16:186-97. DOI |
6 | Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993;34:1357-63. DOI |
7 | Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. |
8 | Briars G. Intestinal inflammation in cystic fibrosis. Arch Dis Child 2001;84:374-5. DOI |
9 | Mack DR, Flick JA, Durie PR, Rosenstein BJ, Ellis LE, Perman JA. Correlation of intestinal lactulose permeability with exocrine pancreatic dysfunction. J Pediatr 1992;120:696-701. DOI |
10 | Rumman N, Sultan M, El-Chammas K, Goh V, Salzman N, Quintero D, et al. Calprotectin in cystic fibrosis. BMC Pediatr 2014;14:133. DOI |
11 | Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 2004;72:6040-9. DOI |
12 | Werlin S, Benuri-Silbiger I, Cohen L, Kerem E, Aviram M, Bentur L, et al. Enteropathy - a new finding in cystic fibrosis. J Cyst Fibros 2008;7 Suppl 2:S79. |
13 | Coffey MJ, Nielsen S, Wemheuer B, Kaakoush NO, Garg M, Needham B, et al. Gut microbiota in children with cystic fibrosis: a taxonomic and functional dysbiosis. Sci Rep 2019;9:18593. DOI |
14 | Dorsey J, Gonska T. Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine. J Cyst Fibros 2017;16 Suppl 2:S14-23. DOI |
15 | Hoen AG, Li J, Moulton LA, O'Toole GA, Housman ML, Koestler DC, et al. Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis. J Pediatr 2015;167:138-47.e1-3. DOI |
16 | Schnapp Z, Hartman C, Livnat G, Shteinberg M, Elenberg Y. Decreased fecal calprotectin levels in cystic fibrosis patients after antibiotic treatment for respiratory exacerbation. J Pediatr Gastroenterol Nutr 2019;68:282-4. DOI |
17 | Adriaanse MP, van der Sande LJ, van den Neucker AM, Menheere PP, Dompeling E, Buurman WA, et al. Evidence for a cystic fibrosis enteropathy. PLoS One 2015;10:e0138062. DOI |
18 | Werlin SL, Benuri-Silbiger I, Kerem E, Adler SN, Goldin E, Zimmerman J, et al. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2010;51:304-8. DOI |
19 | Garg M, Leach ST, Coffey MJ, Katz T, Strachan R, Pang T, et al. Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children. J Cyst Fibros 2017;16:631-6. DOI |
20 | Garg M, Leach ST, Pang T, Needham B, Coffey MJ, Katz T, et al. Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10years old. J Cyst Fibros 2018;17:109-13. DOI |
21 | Marsland BJ, Gollwitzer ES. Host-microorganism interactions in lung diseases. Nat Rev Immunol 2014;14:827-35. DOI |
22 | Hery-Arnaud G, Boutin S, Cuthbertson L, Elborn SJ, Tunney MM. The lung and gut microbiome: what has to be taken into consideration for cystic fibrosis? J Cyst Fibros 2019;18:13-21. DOI |
23 | Roesch EA, Nichols DP, Chmiel JF. Inflammation in cystic fibrosis: an update. Pediatr Pulmonol 2018;53(S3):S30-50. DOI |
24 | Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros 2015;14:419-30. DOI |
25 | Lubamba B, Dhooghe B, Noel S, Leal T. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem 2012;45:1132-44. DOI |
26 | de Freitas MB, Moreira EAM, Tomio C, Moreno YMF, Daltoe FP, Barbosa E, et al. Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis. PLoS One 2018;13:e0198457. DOI |
27 | Taylor-Cousar JL, Von Kessel KA, Young R, Nichols DP. Potential of anti-inflammatory treatment for cystic fibrosis lung disease. J Inflamm Res 2010;3:61-74. |
28 | Wiecek S, Wos H, Kordys-Darmolinska B, Sankiewicz-Szkolka M, Grzybowska-Chlebowczyk U. The concentration of calprotectin in the stools of children with diagnosed cystic fibrosis. Prz Gastroenterol 2017;12:38-43. DOI |
29 | Sabharwal S. Gastrointestinal manifestations of cystic fibrosis. Gastroenterol Hepatol (N Y) 2016;12:43-7. |
30 | Bruzzese E, Callegari ML, Raia V, Viscovo S, Scotto R, Ferrari S, et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS One 2014;9:e87796. DOI |
31 | Parisi GF, Papale M, Rotolo N, Aloisio D, Tardino L, Scuderi MG, et al. Severe disease in Cystic Fibrosis and fecal calprotectin levels. Immunobiology 2017;222:582-6. DOI |
32 | Melsen WG, Bootsma MC, Rovers MM, Bonten MJ. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect 2014;20:123-9. DOI |
33 | Dhaliwal J, Leach S, Katz T, Nahidi L, Pang T, Lee JM, et al. Intestinal inflammation and impact on growth in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2015;60:521-6. DOI |
34 | Fraser-Pitt D, O'Neil D. Cystic fibrosis - a multiorgan protein misfolding disease. Future Sci OA 2015;1:FSO57. |
35 | Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-5. DOI |
![]() |